Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 34 n° 25

Posts Tagged ‘cantor’

Cantor Global Healthcare Conference

Posted by fidest press agency su martedì, 1 ottobre 2019

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:55 a.m. ET in New York.
A live webcast will be available under “Events & Presentations” in the Investors section of the Company’s website located at http://www.xencor.com. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days following the presentation.Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 14 candidates engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit http://www.xencor.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

The 2019 Cantor Global Healthcare Conference

Posted by fidest press agency su lunedì, 30 settembre 2019

ArQule, Inc. (Nasdaq: ARQL) announced that Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 2:25 p.m. ET at the InterContinental New York Barclay in New York City.The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, http://www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of four drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s pipeline includes: ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options; miransertib (ARQ 092), a potent and selective inhibitor of the AKT serine/threonine kinase, in a planned registrational trial with cohorts in Proteus syndrome and PROS to initiate in 2019; ARQ 751, a next generation highly potent and selective AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA in collaboration with Basilea and Sinovant. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cantor Global Healthcare Conference

Posted by fidest press agency su domenica, 29 settembre 2019

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 2019 Cantor Global Healthcare Conference. The presentation is scheduled to begin at 11:15 a.m. ET on Friday, October 4, 2019.
A live webcast of the presentation can be accessed on the “Investors & Media” section of the Aldeyra website, http://www.aldeyra.com. An audio replay will be available following the live presentation and will be archived on the website for 90 days.Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra’s lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cantor Global Healthcare Conference

Posted by fidest press agency su sabato, 28 settembre 2019

Change Healthcare Inc. (Nasdaq: CHNG), a leading independent healthcare technology company, announced today that it will present at the 2019 Cantor Global Healthcare Conference, to be held Oct. 2-4, 2019, at The InterContinental New York Barclay in New York City. Change Healthcare will present on Friday, Oct. 4, at 10:40 a.m. (EDT). A simultaneous live audio webcast will also be available.A webcast replay of the presentation will be available afterward via the Company’s website at changehealthcare.com, under the “Investors” section.
Change Healthcare (Nasdaq: CHNG) is a leading independent healthcare technology company that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system. We are a key catalyst of a value-based healthcare system, accelerating the journey toward improved lives and healthier communities. Learn more at changehealthcare.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cantor Global Healthcare Conference

Posted by fidest press agency su lunedì, 23 settembre 2019

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 9:30 a.m. Eastern Time in New York, NY.A live audio webcast of the presentation will be available by visiting the “Investors” section of the Arcus website at http://www.arcusbio.com. A replay of the webcast will be available for at least 30 days following the live event.
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has four programs in the clinic targeting important oncology/immuno-oncology pathways: (1) AB928, a dual adenosine receptor antagonist (A2a and A2b receptors), being evaluated in several Phase 1/1b trials in combination with multiple regimens across a range of tumor types, (2) AB680, a small molecule inhibitor of CD73 progressing into a Phase 1/1b pancreatic cancer trial, (3) AB122, an anti-PD-1 antibody progressing into a biomarker-selected tumor-agnostic Phase 1b trial, and (4) AB154, an anti-TIGIT antibody being evaluated in combination with AB122. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. Utilizing these unique capabilities, Arcus has created a world-class drug discovery organization focused on the development of a growing portfolio of innovative therapies for the treatment of cancer. For more information about Arcus Biosciences, please visit http://www.arcusbio.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »